In 2018, the market size of global Non-Invasive Prenatal Testing (NIPT) Market was projected at USD 2.09 billion. The usage of these tests leads to advantages like remarkable decline in the number of expensive and risky incursive amniocentesis and Chorionic Villus Sampling (CVS) methods are anticipated to enhance the volumetric capabilities of the market globally which further precisely influence the revenue growth of this market at a wider level.
The Non-Invasive Prenatal Testing (NIPT) Market is driven by rise in indemnity for the NIPT sector, enhanced shift from invasive methods to non-invasive methods, and hike of maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Moreover, market growth is charged by introduction and development of advanced and innovative technologies and non-invasive prenatal testing products. Nevertheless, the market growth is confined due to paucity of skilled professionals as well as rigid regulatory guidelines and ethical hindrance downturn the procedure of approvals and marketing. Evolution of new market in Asia-Pacific region foster for growth prospects for this market.
The Non-Invasive Prenatal Testing (NIPT) Market is classified on the basis of product, method, application, end users, and region. Consumables and instruments are the two segments based on product. On the grounds of method, it is segregated into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, and fetal cells in maternal blood tests. Trisomy, microdeletion syndrome, and other applications are the divisions based on application. Geographically, the market is divided into North America, Europe, Asia-Pacific, and LAMEA.
In 2019, the maximum share registered by North America. Capital intensive, huge R&D investment markets and their associated development reliance that are essential to the progress are among various factors. Additionally, it is anticipated that during the forecast period the growth of North America NIPT market is impacted by factors like the accessibility of technologically leading healthcare research framework and the expansion of WGS in the region.
The Non-Invasive Prenatal Testing (NIPT) Market prominent player includes Ge Healthcare (General Electric Company), Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., Agilent Technologies, Inc., and Beijing Genomics Institute.
• The study provides an in-depth analysis of the non-invasive prenatal testing market, with current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis from 2020 to 2027 to enable the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis of the market by product type elucidates various forms of non-invasive prenatal testing available.
• Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
Non-Invasive Prenatal Testing (NIPT) Market Key Segmentation:
o Assay Kits & Reagents
o Ultrasound Devices
o Next-Generation Sequencing Systems
o Polymerase Chain Reaction Instruments
o Other Instruments
• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Microdeletion Syndrome
• Other Applications
By End User
• Diagnostic Laboratories
• North America
o Rest of Europe
o Rest of Asia-Pacific
o Saudi Arabia
o South Africa
o South Korea
o Rest of LAMEA
TOC NOT FOUND
Abstract Market Research
Call at: +1-209-813-4101 | +91-9730047721